Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22500684 | 0.97 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL11525596 | 0.95 | LMNA (0.60) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL11526051 | 0.95 | LMNA (0.60) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL25760 | 0.95 | ALDH1A1 (0.56) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL24419962 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL22500735 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL22500995 | 0.90 | LMNA (0.68) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL1980081 | 0.90 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| SCHEMBL23388995 | 0.90 | ALDH1A1 (0.50) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 | |
| Ethylene Glycol SCHEMBL3791681 | 0.86 | ALDH1A1 (0.50) | SMN1; SMN2TSHRLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9871270-B2 | Functionalized ionic liquids and their applications | MATERIALS MODIFICATION, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170170518-A1 | Functionalized Ionic Liquids and Their Applications | MATERIALS MODIFICATION INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170170518-A1 | Functionalized Ionic Liquids and Their Applications | FLNA, FLNB, AXL | SMN1; SMN2 623/4885TSHR 2928/4885LMNA 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.